Weight Loss
Semaglutide vs. tirzepatide: how the two weight loss medications compare
How semaglutide and tirzepatide work, what clinical trials show about weight loss, how side effects compare, and the factors that guide which one a physician may recommend.
· 2 min read
Semaglutide and tirzepatide are both weekly injectable medications used for medical weight loss. Semaglutide acts on one appetite-related hormone pathway (GLP-1), while tirzepatide acts on two (GLP-1 and GIP). In clinical trials, both led to significant weight loss, with tirzepatide producing somewhat greater average results. The better choice for any individual depends on their health history, goals, tolerance, and access.
How semaglutide works
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone released after eating that helps regulate appetite, increases fullness, and slows stomach emptying. It is the active ingredient in brand-name medications such as Wegovy and Ozempic.
How tirzepatide works
Tirzepatide activates both GLP-1 and GIP receptors. GIP is another hormone involved in how the body handles food and blood sugar. Acting on both pathways is thought to contribute to its effect on appetite and weight. It is the active ingredient in brand-name medications such as Zepbound and Mounjaro.
What the research shows
In major clinical trials of adults with obesity, participants taking semaglutide lost an average of roughly 15 percent of their body weight over about 68 weeks. Participants taking the highest dose of tirzepatide lost an average of roughly 20 percent over about 72 weeks. Both trials included lifestyle counseling, and individual results varied widely.
Side effects
The two medications have similar side effect profiles. The most common are digestive: nausea, diarrhea, constipation, and reduced appetite, usually most noticeable after a dose increase. Both are started at a low dose and increased gradually to improve tolerance.
Factors that guide the choice
- Your weight loss goals and overall health history
- Other conditions, such as type 2 diabetes or cardiovascular risk
- How you tolerate the medication once you start
- Cost, insurance coverage, and availability
- Your physician’s assessment of your labs and medical history
Who should not take either medication
Neither medication is used in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, or during pregnancy. A full medical review is needed before either is prescribed.
Not sure which option fits you? Book a free consultation to talk through your goals and history with a physician.
This article is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified physician about your individual situation.